Synaptogen
Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead Drug Candidate, Bryostatin-1, for the Treatment of Advanced …
is lower in apoE4 transgenic mice compared with apoE3 mice, indicating impaired synaptogen-esis (12, 13). ApoE4 is less efficient than apoE3 in transporting brain cholesterol (14) and is …
Synaptogenix | Neurotrope Appoints Charles S. Ramat and Paul …
Plantation, FL. – June 19, 2014 – Neurotrope, Inc. (OTCQB: NTRP) has appointed Messrs. Charles S. Ramat and Paul Freiman as Co-Chairmen of its Board of Directors. Mr. Freiman …
Morgantown, WV 26505 Running title: Rescuing synapses and spatial memory in young fragile X mice
Neurotrope Launches New Long-Term Clinical Trial of
NEW YORK, May 28, 2020 – Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer’s disease …
Synaptogenix | Neurotrope, Inc., Announces Hiring Robert …
Plantation, FL. – October 7, 2013 – Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB:NTRP), a Nevada corporation (the “Company”), announced today that it has formally …
Synaptogenix | Neurotrope’s President and Chief Scientific Officer …
NEW YORK, March 24, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, …
Neurotrope Announces Cooperative Research and Development
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute
Dec 5, 2014 · Apolipoprotein E (ApoE) is a critical signal for synaptogen-esis and synaptic maturation [101]. ApoE/cholesterol com-plex released from astrocytes is taken up through low …
Traumatic brain injury (TBI) is a frequent consequence of vehicle, sport and war related injuries. More than 90% of TBI patients suffer mild injury (mTBI). However, the pathologies underlying …